Cellectis getting $28M for allogeneic CAR T-cell therapy

By Cormac SheridanStaff Writer

Tuesday, April 1, 2014

Cellectis SA completed a €20.5 (US$28.3 million) million private placement with a syndicate of U.S. investors to use its suite of technologies for engineering T cells and chimeric antigen receptors (CARs) in the development an allogeneic cell therapy based on CAR-transduced T cells.